Revised Guidance To Clarify Adverse Event Reporting Requirements In Europe
This article was originally published in The Gray Sheet
Executive Summary
The revision of supplemental guidelines to the European Medical Device Directive (MDD) should help further clarify manufacturer obligations for postmarket event reporting, speakers suggested March 2 at IBC Life Sciences' Vigilance & Postmarket Surveillance for Medical Devices conference in London
You may also be interested in...
United Kingdom Issues New Adverse Event Reporting Guidelines
New guidelines spell out that manufacturers who sell medical devices in the United Kingdom have no more than two calendar days after becoming aware of a "serious public health threat" to file an initial adverse event report with the country's Medicines and Healthcare Products Regulatory Agency
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.